Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Barrett-Lee

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Clinical Oncology (Royal College of Radiologists (Great Britain))|August 21, 2007
Improving adjuvant chemotherapy in breast cancer -- can we get more for less with TACT2?L Johnson, D Cameron, P Barrett-Lee, et al.
Breast (Edinburgh, Scotland)|February 18, 2004
Male cancer: a qualitative study of male breast cancerL France, S Michie, P Barrett-Lee, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|August 17, 2010
HER2 testing, adjuvant trastuzumab use and results. Our experience in South WalesR Webster, N Palaniappan, J Abraham, et al.
Breast (Edinburgh, Scotland)|October 30, 2012
A prognostic tool to predict fatigue in women with early-stage breast cancer undergoing radiotherapyN Courtier, T Gambling, S Enright, et al.
British Journal of Cancer|November 13, 2003
Experiences of men with breast cancer: an exploratory focus group studyB G Williams, R Iredale, K Brain, et al.
British Journal of Cancer|November 24, 2011
Exploring the use and impact of adjuvant trastuzumab for HER2-positive breast cancer patients in a large UK cancer network. Do the results of international clinical trials translate into a similar benefit for patients in South East Wales?R M Webster, J Abraham, N Palaniappan, et al.
British Journal of Cancer|June 1, 1993
The prognostic significance of transforming growth factors in human breast cancerP A Murray, P Barrett-Lee, M Travers, et al.
British Journal of Cancer|April 3, 2014
Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer networkA Borley, T Mercer, M Morgan, et al.
European Journal of Cancer (Oxford, England : 1990)|July 29, 2014
Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001)E Hall, D Cameron, R Waters, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 5, 2005
Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapyE De Cock, J Hutton, P Canney, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Clinical Oncology (Royal College of Radiologists (Great Britain))|August 21, 2007
Improving adjuvant chemotherapy in breast cancer -- can we get more for less with TACT2?L Johnson, D Cameron, P Barrett-Lee, et al.
Breast (Edinburgh, Scotland)|February 18, 2004
Male cancer: a qualitative study of male breast cancerL France, S Michie, P Barrett-Lee, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|August 17, 2010
HER2 testing, adjuvant trastuzumab use and results. Our experience in South WalesR Webster, N Palaniappan, J Abraham, et al.
Breast (Edinburgh, Scotland)|October 30, 2012
A prognostic tool to predict fatigue in women with early-stage breast cancer undergoing radiotherapyN Courtier, T Gambling, S Enright, et al.
British Journal of Cancer|November 13, 2003
Experiences of men with breast cancer: an exploratory focus group studyB G Williams, R Iredale, K Brain, et al.
British Journal of Cancer|November 24, 2011
Exploring the use and impact of adjuvant trastuzumab for HER2-positive breast cancer patients in a large UK cancer network. Do the results of international clinical trials translate into a similar benefit for patients in South East Wales?R M Webster, J Abraham, N Palaniappan, et al.
British Journal of Cancer|June 1, 1993
The prognostic significance of transforming growth factors in human breast cancerP A Murray, P Barrett-Lee, M Travers, et al.
British Journal of Cancer|April 3, 2014
Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer networkA Borley, T Mercer, M Morgan, et al.
European Journal of Cancer (Oxford, England : 1990)|July 29, 2014
Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001)E Hall, D Cameron, R Waters, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 5, 2005
Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapyE De Cock, J Hutton, P Canney, et al.
Pageof 3